These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evolution of plasma specific fibrin degradation products during thrombolytic therapy in patients with thrombo-embolism. Faivre R; Mirshahi M; Ducellier D; Soria C; Soria J; Mirshahi M; Kieffer Y; Bassand JP; Caen J; Maurat JP Thromb Res; 1988 May; 50(4):583-9. PubMed ID: 3413720 [No Abstract] [Full Text] [Related]
4. Selection of patients with pulmonary embolism for thrombolytic therapy. Kakkar VV; Raftery EB Lancet; 1970 Aug; 2(7666):237-41. PubMed ID: 4193690 [No Abstract] [Full Text] [Related]
5. [Pulmonary embolism: what happens to the emboligenic focus?]. Serradimigni A; Philip F; Elias A; Lecorff G Haemostasis; 1986; 16 Suppl 4():69-78. PubMed ID: 3770559 [No Abstract] [Full Text] [Related]
6. Treatment of pulmonary embolism and deep vein thrombosis with thrombolytic therapy. Volgesang GB; Bell WR Clin Chest Med; 1984 Sep; 5(3):487-94. PubMed ID: 6386293 [TBL] [Abstract][Full Text] [Related]